Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
AVANIR PHARMACEUTICALS, INC. (AVNR)
|
Add to portfolio |
|
|
|
| Price: |
$2.81
| | Metrics |
| OS: |
193.8
|
M
| |
-18
|
% ROE
|
| Market cap: |
$544
|
M
| |
-279
|
% ROIC
|
|
Net cash:
|
$272
|
M
| |
$1.40
|
per share
|
|
EV:
|
$273
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($44.9)
|
M
| |
|
|
|
EBIT
|
($46.3)
|
M
| |
|
|
| EPS |
($0.32)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-14 | Sep-30-13 | Sep-30-12 | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 |
| Revenues | 115.0 | 75.4 | 41.3 | 10.5 | 2.9 | 8.4 | 0.1 | 0.1 |
| Revenue growth | 52.6% | 82.6% | 293.2% | 262.5% | -65.3% | 6334.3% | 80.3% | 294.1% |
| Cost of goods sold | 3.5 | 4.2 | 2.1 | 0.4 | 0.2 | 0.1 | 0.0 | 0.3 |
| Gross profit | 111.5 | 71.2 | 39.2 | 10.0 | 2.7 | 8.3 | 0.1 | -0.3 |
| Gross margin | 96.9% | 94.5% | 94.9% | 95.8% | 93.2% | 99.1% | 83.3% | -355.8% |
| Selling, general and administrative | | | | | 16.5 | 10.2 | 10.6 | |
| Sales and marketing | 77.7 | 63.2 | 52.5 | 38.1 | | | | |
| Research and development | 44.0 | 49.5 | 23.1 | 15.3 | 13.3 | 15.9 | 14.1 | 13.1 |
| General and administrative | 36.2 | 29.9 | 22.0 | 17.3 | | | | 20.8 |
| EBIT | -46.3 | -71.4 | -58.4 | -60.6 | -27.1 | -21.9 | -19.0 | -29.4 |
| EBIT margin | -40.3% | -94.8% | -141.5% | -577.6% | -935.8% | -262.5% | -14606.7% | -40790.1% |
| Pre-tax income | -50.4 | -75.5 | -59.7 | -60.6 | -26.7 | -22.0 | -15.9 | -28.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | | |
| Earnings from continuing ops | -50.4 | -75.5 | -59.7 | -60.6 | -26.7 | -22.0 | -15.9 | -20.9 |
| Earnings from discontinued ops | | | | | | | -1.4 | 7.4 |
| Net income | -50.4 | -75.5 | -59.7 | -60.6 | -26.7 | -22.0 | -17.5 | -20.9 |
| Net margin | -43.8% | -100.1% | -144.7% | -577.7% | -921.9% | -263.3% | -13476.9% | -29074.2% |
| |
| Diluted EPS | ($0.31) | ($0.53) | ($0.45) | ($0.51) | ($0.30) | ($0.28) | ($0.27) | ($0.53) |
| Shares outstanding (diluted) | 161.3 | 142.3 | 133.4 | 119.4 | 87.6 | 78.8 | 58.9 | 39.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|